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ABSTRACT 
 
In previous studies we described the use of a retrospective 
collection of ovarian cancer and benign disease samples, in 
combination with a large set of multiplexed immunoassays 
and a multivariate pattern recognition algorithm, to develop 
an 11-biomarker classification profile that is predictive for 
the presence of epithelial ovarian cancer.  In this study, 
customized, Luminex-based multiplexed immunoassay kits 
were GMP-manufactured and the classification profile was 
refined from 11 to 8 biomarkers (CA-125, epidermal 
growth factor receptor, CA 19-9, C-reactive protein, 
tenascin C, apolipoprotein AI, apolipoprotein CIII, and 
myoglobin).  The customized kits and the 8-biomarker 
profile were then validated in a double-blinded manner 
using prospective samples collected from women scheduled 
for surgery, with a gynecologic oncologist, for suspicion of 
having ovarian cancer.  The performance observed in model 
development held in validation, demonstrating 81.1% 
sensitivity (95% CI 72.6 – 87.9%) for invasive epithelial 
ovarian cancer and 85.4% specificity (95% CI 81.1 – 88.9%) 
for benign ovarian conditions.  The specificity for normal 
healthy women was 95.6% (95% CI 83.6 – 99.2%).  These 
results have encouraged us to undertake a second validation 
study arm, currently in progress, to examine the 
performance of the 8-biomarker profile on the population of 
women not under the surgical care of a gynecologic 
oncologist.   
 
 
INTRODUCTION 
 
Ovarian cancer is the most lethal gynecological cancer.  
Within the USA, there are approximately 21,880 new cases 
and 13,850 deaths each year.1  More than 80% of these cases 
are detected as late stage disease with poor survival rates.1,2  
The best clinical outcome for patients with advanced disease 
depends upon complete surgical staging and optimal 
debulking.3  These are complex surgeries that are best 
performed by gynecologic oncologists.4,5  However, in the 
USA, more than 50% of women with ovarian cancer receive 
care from non-specialists and up to 80% of these individuals 
receive inadequate staging.4,6  Since only 13-21% of women 
scheduled for surgery based on symptoms consistent with 
ovarian cancer, actually have ovarian cancer, and there are 
only ~ 1,000 of board certified gynecologic oncologists in 
the USA, a test that can both increase the number of cancer 
cases referred to a specialist, and increase the prevalence of 
cancers within that referred population, by minimizing the 
number of benign referrals, would be useful.   
 
There are no highly accurate tests for the detection of 
ovarian cancer.  For the assessment of cancer risk, an 
oncologist usually assesses multiple non-specific lines of 
evidence including family history, patient symptoms, a 
physical examination, a radiographic evaluation, and 
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laboratory findings.  The common symptoms associated 
with the disease, such as pelvic and abdominal pain, urinary 
urgency, urinary frequency, abdominal bloating, and 
difficulty eating, do not differentiate well between cancerous 
and benign conditions.7  A physical exam and radiographic 
evidence can help in the detection of a pelvic mass, however 
the commonly used imaging techniques – transvaginal 
sonography (TVS), positron-emission tomography (PET), 
magnetic resonance imaging (MRI), radio-
immunoscintigraphy and computed tomography (CT) – 
tend to have a low specificity in the hands of many 
radiographers.8  While some reports suggest ultrasound 
alone, or in combination with other prognostic variables, 
may be significantly more informative in the hands of an 
ovarian ultrasound expert,9,10 many patients lack access to 
such specialized imaging services.   
 
Most laboratory findings focus on the elevation of CA-125 
associated with ovarian cancer.  However, despite 
widespread use, CA-125 is not FDA-approved for 
diagnosis.  A critical drawback for CA-125 is a lack of 
specificity, being elevated in many normal/benign 
conditions and non-ovarian malignancies.11-13  Approaches 
to improve the predictive value of CA-125 through serial 
measurements,14,15 or in combination with additional 
markers,16,17 have been reported, but remain under study.   
 
Professional societies, such as ACOG/SGO have provided 
recommended guidelines for referral to a specialist18-21 and 
at least one report has suggested a unique combination of 
symptoms, if fully documented for each patient, may be 
more informative than previously recognized.22  Despite 
these advances, more than 80% of patients referred to a 
specialist will have a benign condition.8,23,24   
 
In the absence of a single informative biomarker, attention 
has focused on the combination of multiple biomarkers, in 
conjunction with non-obvious algorithms, to create 
multivariate index assays.  Progress on three multivariate 
biomarker algorithms has been reported recently.  A six-
biomarker panel, composed of leptin, prolactin, osteopontin, 
insulin-like growth factor II, macrophage inhibitory factor, 
and CA-125 was reported to have a sensitivity of 95.3% and 
a specificity of 99.4%.25  However, these results were not 
validated using independent samples, and contained a 
notable population bias, with all cases representing women 
committed to surgery for ovarian exploration, and all 
controls representing apparently healthy women attending a 
regular gynecologic exam.  A 2-biomarker assay (risk of 
malignancy algorithm; ROMA), based on CA-125 and HE4 
has also been reported recently.17  This assay uses separate 
algorithms for pre- and post-menopausal patients.  For 
post-menopausal women, at a fixed specificity of 75.0% 
(95% CI 66.9 – 81.4%), the sensitivity was 92.3% (95% CI 
85.9 – 96.4%).  For pre-menopausal women, at a fixed 
specificity of 74.8% (95% CI 68.2 – 80.6%) the sensitivity 
was 76.5% (95% CI 58.8 – 89.3%).  Unfortunately this study 
failed to use an independent validation sample set, the 
validation samples being used themselves to identify the 
ROMA cut-off values that yielded the “clinically acceptable” 
75% specificity.  Therefore the performance of this assay, 
with pre-established cut-off values, remains unknown.  
Most recently, OVA1, a 5-biomarker ovarian malignancy 
assay, combining CA-125, transthyretin, apolipoprotein A-
I (ApoA-I), transferrin, and beta-2 microglobulin has been 
validated in a prospective, blinded clinical study submitted 
to the USA Food and Drug Administration (FDA).26  The 
results have yet to be published.  In the FDA regulatory 
documents,26 the performance of the assay varies 
significantly depending on the source of the surgical patient 
population (specialist or non-specialist oncologist), the 
menopausal status of the patient, and whether the assay is 
combined with a pre-surgical impression or not.  Across 
these scenarios, the sensitivity of test lies between 80.8 and 
98.9%, while the specificity ranges between 24.4 and 56.8%.  
In general, sensitivity increased at the expense of specificity 
for post-menopausal women.  A similar trend occurred 
when the biomarker results were combined with pre-
surgical assessment.  This biomarker assay is not for stand-
alone use or screening, but for referral of a restricted subset 
of surgical patients, in the care of a non-specialist, whose 
pre-surgical assessment does not indicate malignancy.  
Since the low specificity yields a high false positive rate, a 
test with a higher specificity could improve specialist 
referral by lowering the over-referral of benign cases.   
 
In previous work we described a biomarker discovery 
approach in which we profiled stage I invasive epithelial 
ovarian cancer (EOC) and ovarian benign conditions, using 
a highly multiplexed immunoassay discovery platform.27,28  
Our hypothesis was that by avoiding the use of late stage 
cancers in discovery, which have elevated CA-125 levels, we 
would identify biomarkers independent of CA-125.  From a 
total of 204 biomarkers we identified a unique combination 
of 11 biomarkers, which appeared informative for the 
presence of all stages of invasive EOC in women scheduled 
for surgery.  In preliminary testing using a multi-site 
retrospective collection of stage II-IV EOC and benign 
ovarian condition samples, collected from gynecologic 
oncology practices, this classification profile demonstrated 
a sensitivity of 91.3%  (95% CI 84.2 – 95.5%) and a 
specificity of 88.5% (95% CI 81.4 – 93.2%).  These results 
were very promising.  Following this, we manufactured 
several lots of a custom-designed multiplexed 
immunoassay kit for the 11 biomarkers and used that to 
develop a refined version of this classifier.  The improved 
classifier consists of a subset of 8 biomarkers (CA-125, CA 
19-9, C-reactive protein (CRP), ApoA-I, apolipoprotein 
CIII (ApoC-III), epidermal growth factor receptor (EGF-R), 
myoglobin and tenascin C).  We now report a completely 
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independent validation of this 8-biomarker profile using a 
prospectively collected set of samples from gynecologic 
oncologists practices.  Using a double-blinded experimental 
protocol, we show that the validated performance is 
consistent with the results seen along the biomarker 
discovery pathway, exhibiting a sensitivity of 81.1% (95% 
CI 72.6 – 87.9%) and specificity of 85.4% (95% CI 81.1 – 
88.9%), validating our biomarker discovery strategy.  We 
also show that the classifier meets the generally accepted 
criterion of an informative test.   
 
MATERIALS AND METHODS 
 
Prospective Patient Population 
Sera from 1398 qualified individual participants were 
collected prospectively for the purpose of validating an 
ovarian cancer test.  Of these, 260 had EOC, with 213 of the 
260 being invasive and 47 being borderline-low malignant 
potential (LMP) cases.  Twelve gynecologic oncology sites 
participated in the study, which was approved by the 
Institutional Review Board (IRB) of each participating site 
and by the Western IRB (Olympia, WA) for Correlogic 
Systems Inc. (Germantown, MD) under Study Number 
1064143.  The sites were Cedars-Sinai Medical Center; 
Wake Forest University, Winston-Salem; SUNY at Stony 
Brook; Florida Hospital Cancer Institute; Holy Cross 
Hospital; Florida Gynecologic Oncology; University of 
Southern California: Norris Cancer Center and Women’s 
and Children’s Hospital; Women and Infants Hospital of 
Rhode Island; University of Alabama; North Shore – Long 
Island Jewish Health System; and The Harry and Jeanette 
Weinberg Cancer Institute at Franklin Square Hospital.  All 
sites provided both patients with EOC and benign ovarian 
conditions. 
 
The study inclusion criteria were women, at least 18 years of 
age, symptomatic of ovarian cancer according to the 
National Comprehensive Cancer Network (NCCN) Ovarian 
Cancer Treatment Guidelines for Patients,7 which includes 
women with or without a pelvic mass.  Participants had to 
be scheduled for gynecologic surgery based on concern they 
had ovarian cancer, and post-surgical pathological 
evaluation of the ovaries and excised tissues was required.  
Exclusion criteria were women who did not meet the 
inclusion criteria, could not provide informed consent, were 
pregnant, or previously treated for ovarian cancer.   
 
Prospective Serum Collection 
Sera were collected, prior to intervention, using a well-
defined blood collection protocol.  Briefly, blood was drawn 
into red top Vacutainer tubes (Becton, Dickinson and 
Company; Franklin Lakes, NJ), clotted for at least 30 
minutes at room temperature and centrifuged at 1,300g, at 
room temperature, to separate serum.  Sera were then 
transferred to screw-top cryogenic vials and frozen (-80°C) 
within 2 hours of the draw.  None of the samples used in the 
validation study were thawed or used in any manner prior to 
this validation study.   
 
Nominally Healthy Individuals 
Sera from healthy volunteers were collected by a 
commercial specimen bank (ProMedDx; Norton, MA) that 
was not involved in the gynecologic oncology collection.  
Sera were collected, using the same blood collection 
protocol, from 45 women (aged 19-62) and from 30 males 
(aged 18-57).  A health review questionnaire was completed 
for each participant but ovarian pathology was not available 
for the women.   
 
Blinding of Serum Samples and Clinical Data 
The serum samples were blinded to both the analytical 
testing site, Rules-Based Medicine (RBM; Austin, TX), and 
the classification scoring site, Correlogic Systems, Inc.  An 
independent, contract statistician experienced in clinical 
study design, identified the specific subset of samples to use 
in the study in a manner designed to ensure they were 
representative of the larger prospective collection.  Two 
independent contract research organizations (CRO) worked 
with the statistician.  CRO-1 performed all sample handling 
including masking, labeling, aliquoting, and shipping to the 
analytical test site.  CRO-2 performed electronic encoding 
of the patient data and, following the classification of the 
masked samples, linked the results to the patient data for 
analysis by the statistician.  
 
Study Design and Sample Size 
The study was designed to demonstrate whether the 8-
biomarker profile is informative for the detection of EOC in 
women, under the care of a gynecologic oncologist, with 
NCCN-defined symptoms of ovarian cancer, who are 
scheduled for surgery; and to estimate the sensitivity, 
specificity, positive predictive value (PPV), and negative 
predictive value (NPV), of the profile on this population.  
 
A generally accepted criterion for an informative test is that 
the 95% lower confidence level (LCL) for the sum of 
sensitivity and specificity should be greater than 100%.  
Prior to the validation, and based on our model 
development results, we established a more stringent 
hypothesis that the point performances of sensitivity and 
specificity of the 8-biomarker assay should each exceed 80% 
and the exact one-sided LCL of the sum of sensitivity and 
specificity should be greater than 135%. 
 
To achieve statistical significance, the hypothesis study 
design required a minimum of 103 patients with EOC, and 
309 patients with benign ovarian disease.  To accommodate 
any sample handling or assay errors, these numbers were 
increased an additional 10% to give a final sample size of 
113 EOC patients and 335 control patients.  To select 
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samples from the larger prospective collection, the 
statistician stratified the prospective collection by study 
site, to ensure a proportional representation of participating 
clinical sites, and from that selected the required number of 
samples randomly.   
 
Immunoassays 
We previously reported an 11-biomarker profile for 
epithelial ovarian cancer,27 for which we have now 
constructed custom Luminex-based, multiplexed 
immunoassay panels.  The custom kits, designed for an 
automated, high-throughput use, are composed of two 
multiplex panels.  Panel A, an 8-plex composed of assays for 
CA-125, CA 19-9, EGF-R, tenascin C, myoglobin, 
interleukin-6, interleukin-18, and macrophage 
inflammatory protein-1-alpha (MIP-1a), is assayed at a 1:5 
dilution.  Panel B, a 4-plex composed of assays for CRP, 
ApoA-I, ApoC-III, and fibrinogen (a quality check for 
serum) is assayed at a 1:5,000 dilution.  Four independent 
assay lots of these kits were manufactured under good 
manufacturing practices (GMP).  Kits are available 
commercially, for research use only, from Correlogic 
Systems, Inc.   
 
Multiplexed immunoassays were performed in 96-well 
plates at room temperature.  Sera were diluted in phosphate-
buffered saline (PBS) containing 4% bovine serum albumin 
(BSA), pH 7.4 and assayed in a buffer containing 1% BSA, 
0.05% ProClin 300, and a proprietary mix of antibodies and 
domestic animal proteins to minimize non-specific 
interactions.  Each 96 well assay plate contained: 16 wells 
for standards, consisting of 2 sets of 8 different dilutions of 
pooled standards, used to create 8-point calibration curves; 
6 wells of pooled quality controls, consisting of 2 sets of 
low, medium and high levels for each biomarker; and up to 
72 wells for patient samples.  The validation study was 
performed over 2 days using a combination of 3 
manufacturing lots of the immunoassay kits, 5 different 
robots, 11 different Luminex instruments and 2 operators.  
 
The 8-Biomarker Profile 
During the discovery and development phase,27,28 sera were 
analyzed using RBM’s Human MAP v1.6, a set of 
multiplexed assays that measured 204 serum molecules.  
Prior to validation the 11 assays identified in the previous 
work, plus fibrinogen, were reformatted into a custom 
multiplex kit described above.  Since multiplex assay 
performance characteristics change when assays are 
reformatted, the model development analysis previously 
described was repeated, using the same model development 
samples, same modeling strategy and same KDE-VS 
modeling algorithm.27  The only difference this time was 
that the samples were assayed with the custom manufactured 
12-biomarker multiplex kit rather than the multiple panels 
that make up Human MAP v1.6.  Using these new data, the 
11-biomarker classification model was refined to a single 
model that used only 8 of the previous 11 biomarkers (CA-
125, CA 19-9, CRP, ApoA-I, ApoC-III, EGF-R, myoglobin 
and tenascin C), with no statistically significant change in 
performance.  Importantly, none of the samples evaluated in 
the blinded validation study were used in this refinement.   
 
The final classification profile or “model”, consists of a 
series of fixed mathematical rules, that interpret the relative 
concentration of the 8 biomarkers in a patient’s serum.  The 
rules are encoded into a software package that automates the 
analysis27 and provides a simple binary outcome for each 
patient that reflects either a low or high risk of having 
ovarian cancer.   
 
RESULTS AND DISCUSSION 
 
Patient Characteristics 
Women participating in the prospective serum collection 
were scheduled for surgery, based on a concern that they had 
ovarian cancer.  We selected a subset of these women for the 
double-blinded validation study as described in Materials 
and Methods.  A comparison of the key characteristics 
demonstrate that the validation subset fairly represents the 
entire prospective collection (Table 1).   
 
In our study population the incidence of invasive EOC was 
15.2%, the incidence of borderline – low malignant potential 
(LMP) tumors within the EOC was 18.1%.  The incidence of 
any malignancy was 31.3%.  
 
In the overall population the mean age of the EOC patients 
was 61.1 ±11.7 years while women with benign conditions 
had a mean age of 53.2 ± 13.5 years.  A pelvic mass was 
present in 1293 out of 1335 (96.9%) of patients who 
reported pelvic mass information.  Women with EOC 
predominantly had a pelvic mass (211 out of 213) while 
there were slightly more benign cases without a mass (30 
out of 1185).  Of women presenting with EOC, 72.8% were 
self reported as post-menopausal compared to 50.8% of 
women with benign conditions.  The dominant subtype and 
stage of EOC was serous and stage III disease, respectively, 
with distant disease (stage III/IV) representing 63.8% of all 
pathology confirmed EOC and 70.5% of all staged EOC.   
 
Validation Results 
During analysis, two samples were lost due to a pipette 
malfunction.  The remaining samples were successfully 
assayed and classified.  Upon completion of the study, 
unmasking identified both lost samples as stage III cancers 
leaving 111 invasive EOC and 335 benign samples.  The test 
had a sensitivity of 81.1% (95% CI 72.6 – 87.9%) and 
specificity of 85.4% (95% CI 81.1 – 88.9%; Table 2).  The 
exact one-sided LCL of the sum of the sensitivity and 
specificity for the validation sample set was 160% yielding a 
normal z statistic of 7.5 (p < 0.0001).   
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Table 1.  Comparison of the Prospective Collection to the Blinded Validation Subset 
 
  Prospective Collection  Validation Study 
Total patients n (%)  1398  448 * 
Invasive EOC  213  113 * 
                    FIGO Stage   I  35 (16.4)  17 (15.0) 
                                         II  22 (10.3)  10 (8.8) 
                                        III  125 (58.7)  70 * (61.9) 
                                        IV  11 (5.2)  6 (5.3) 
Stage unknown  20 (9.4)  10 (8.8) 
Benign ovarian condition  930  335 
Other gynecologic malignancy  224 †  0 
Pathology not definitive  31  0 
Age – Mean (±SD)     
Invasive EOC  61.1 (±11.7) ‡  61.4 (±11.5) 
Benign condition  53.2 (±13.5) §  53.0 (±14.5) 
Pelvic Mass n (%)     
Present  1293 (96.9)  439 (98.0) 
Absent  42 (3.1)  9 (2.0) 
No information  63 (N/A)  0 (N/A) || 
* Includes two stage III EOC samples which were not assayed due to a technical problem.  † 89 of these samples were assayed following 
completion of the validation study, see Table 5. ‡ Age not reported for one individual, calculation based on 212 individuals.  § Age not 
reported for six individuals, calculation based on 920 individuals. || Pelvic mass information was required.  Abbreviations: EOC, 
epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; SD, standard deviation.   
 
 
These findings met the criteria established prior to the 
study, independently validating the performance of the 8-
biomarker classification profile, meeting our pre-validation 
definition of an informative test, and meeting the generally 
accepted criteria of a clinically useful test.29   
 
There was no statistical difference in either the sensitivity or 
specificity of the 8-biomarker profile when patients with or 
without a pelvic mass were compared (Table 2).  The one 
EOC and eight benign samples from patients without 
masses were all classified correctly.  While the performance 
for symptomatic women lacking a pelvic mass is promising, 
the low number of these patients does not provide sufficient 
statistical support to validate the profile as informative 
within this group.   
 
PPV and NPV 
The 25% prevalence of EOC in the subset of prospective 
samples used in the validation study was a product of the 
statistical design of the hypothesis study.  In the entire 
prospective collection, representative of the studied 
population, the prevalence was 15.2%.  Extrapolation of the 
measured sensitivity and specificity of this population to the 
entire collection yields a PPV of 49.5% and NPV of 96.2%.   
 
Stage and Subtype of Ovarian Cancer 
The sensitivity for late stage disease (>90%) was greater 
than for early stage disease (Table 3).  In our previous model 
development studies we estimated stage II - IV sensitivity of 
91.3% (95% CI 84.2 – 95.5%).27  In this prospective 
validation we observed a stage II - IV sensitivity of 88.1% 
(95% CI 78.8 – 93.8%), a point estimate lower than the 
initial point estimate, but still within the 95% confidence 
limits and consistent with the differences expected between 
testing estimates and validation.  For specificity, the model 
development estimate of 88.5% (95% CI 81.4 – 93.2%) was 
close to the observed validation specificity of 85.4% (95% 
CI 81.1 – 88.9%). 
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Table 2. Sensitivity, Specificity and Informative Value of the 8-Biomarker Profile 
 
  Epithelial Ovarian Cancer  Benign Conditions 
Population  SN 95% CI n/N  SP 95% CI n/N 
All  81.1% 72.6 – 87.9 90/111  85.4% 81.1 – 88.9 286/335 
Pelvic Mass         
With  80.9% 72.3 – 87.8 89/110  85.0% 80.7 – 88.7 278/327 
Without  100.0% 2.5 – 100.0 1/1  100.0% 63.1 – 100.0 8/8 
Menopause         
Post  80.9% 70.9 – 88.2 72/89  89.2% 83.8 – 93.3 165/185 
Not post  89.5% 65.5 – 98.2 17/19  79.7% 72.2 – 86.0 114/143 
Unknown  33.3% 1.8 – 87.5 1/3  100.0% 59.0 – 100.0 7/7 
Abbreviations: SN, sensitivity; SP, specificity; 95% CI, 95% two-sided exact binomial confidence interval; n, number of samples classified 
correctly; N, number of samples assayed. 
 
 
The retrospective sample set used in model development 
was deliberately enriched for stage I samples.27  Since the 
majority of these samples were used to select the 
biomarkers and develop the classification profile, it had left 
few stage I samples for performance testing.  In those earlier 
development studies, we used bootstrap analysis to estimate 
the profile had a stage I sensitivity of 83.4% ±12.4% with 
the caveat that this strategy limited the statistical confidence 
of this extrapolation.  We could not confirm this 
performance with this study, and indeed this highlights the 
need for caution in interpreting bootstrap estimates in 
biomarker studies.  In our prospective study population, 
stage I disease represented only 16.4% of the staged invasive 
EOC and the small number of stage I cancers prevented 
statistically significant conclusions about early stage 
performance.  While the apparent performance on early 
stage disease was lower than anticipated, the surgical value 
of specialist referral may be much greater for the more 
complex later stage disease, where the profile scored well.4,5  
Sensitivity for the two major subtypes of EOC, serous 
(85.5%) and endometrioid (90.0%) was statistically similar 
(Table 4).  There were too few clear cell, mucinous, 
undifferentiated, transitional cell and Brenner samples to 
make a judgment on these subtypes of EOC.   
 
Other Analyses 
While the double-blinded validation study was limited to 
studying invasive EOC, there is significant interest in LMP 
cancers.  We decided to exclude LMP cancers for the double-
blinded validation study based on several considerations.  In 
the 2001 International Classification of Diseases publication 
(ICD-0-3), the World Health Organization changed the 
classification of LMP tumors, from malignant to non-
malignant, suggesting our study should assign these as 
benign conditions, contributing to estimates of specificity.  
On the other hand, while most LMP tumors are non-
aggressive and respond well to surgery alone, with 10-year 
survival rates in excess of 95%,30 a small proportion (~5%) 
are aggressive, which would suggest they should be grouped 
with EOC and contribute to estimates of sensitivity.  
Finally, there is an increasing concern in the literature that 
detection of LMP represents over-diagnosis.31,32  Given the 
lack of clarity on the classification, we chose to report 
performance on LMP separately to the invasive EOC 
samples.  To this end, the LMP samples were classified in a 
separate single-blinded study.  No preoperative biomarker 
or pathognomonic ultrasound features have been described 
for diagnosing LMP.33  Of the 42 LMP samples tested, 23 
(54.8%) were classified as positive, a near neutral outcome 
(Table 5).   
 
The prospective collection contained other forms of 
gynecologic cancers, beyond EOC, and a selection of these, 
randomized along with sera from a small number of 
apparently healthy male and female donors, were also 
analyzed in blinded manner.  In most instances the number 
of each disease was low, introducing wide confidence 
intervals into the performance estimates (Table 5).  
Although the confidence intervals are wide, the results are 
interesting.  The sensitivity for mixed cancers in which 
ovarian cancer is present with another cancer was 100%.   
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Table 3. Sensitivity of the 8-Biomarker Profile by 
Epithelial Ovarian Cancer FIGO Stage 
 
FIGO 
Stage 
 SN 95% CI n/N 
I  47.1% 23.0 – 72.2 8/17 
II  60.0% 26.2 – 87.8 6/10 
III  91.2% 81.8 – 96.7 62/68 
IV  100.0% 54.1 – 100.0 6/6 
Unknown  80.0% 44.4 – 97.5 8/10 
Abbreviations: FIGO, International Federation of Gynecology 
and Obstetrics; SN, sensitivity; n, number of samples classified as 
ovarian cancer; N, number of samples assayed. 
 
 
The fallopian and peritoneal cancers, which are very similar 
in origin, treatment and outcome to EOC, were detected 
with similar sensitivity (~81%) to EOC.  The malignant 
mixed Mullerian tumors (MMMT) were classified as a 
malignancy in 85.7% of cases, a promising result given CA-
125 is not useful in monitoring most MMMT.  Finally, CA-
125 sensitivity for endometrial/uterine cancers is low 
making the 53.9% detection with the 8-biomarker profile 
interesting.  Together these results suggest that the 8-
biomarker profile is equally informative for other ovarian-
associated malignancies. As anticipated, 100% of male 
specimens were classified as having a profile inconsistent 
with the presence of ovarian cancer.  Only 2 of 45 apparently 
healthy women tested had profiles consistent with ovarian 
cancer (specificity = 95.6%; 95% CI 83.6 – 99.2%), a 
significantly higher specificity than was observed for 
women with benign ovarian conditions (85.4%).  This 
finding underscores the necessity of validating classification 
profiles on case and control samples matching the correct 
intended use population.  Despite the apparently higher 
specificity on nominally healthy women, the 8-biomarker 
profile specificity still reflects an unacceptably high false 
positive rate for a screening application within the general 
population.34   
 
CONCLUSION 
 
In conclusion, using a prospective collection from women 
assessed as at risk of having ovarian cancer, under the care of 
a gynecologic oncologist, we have validated an 8-biomarker 
profile built on a retrospective collection of stage I invasive 
EOC and demonstrated it meets the general requirements of 
an informative test.  We are now focusing on validating an 
improvement of the KDE-VS algorithm that allows us to 
adjust the relative sensitivity and specificity of the profile, 
with the gain in one performance attribute offset by an 
acceptable decrease in the other performance attribute.  At 
the same time we are undertaking a second prospective 
collection, this time focusing on women with symptoms of 
ovarian cancer currently under the care of a non-specialist, 
to determine the validated performance of our assay on the 
intended use population – those women who would benefit 
by referral to a specialist oncologist.   
 
Table 4. Sensitivity of the 8-Biomarker Profile by EOC Subtype 
 
  Multiple Subtypes  Single Subtypes 
Subtype‡  SN 95% CI n/N  SN 95% CI n/N 
Serous  81.4% 71.6 – 89.0 70/86  85.5% 75.0 – 92.8 59/69 
Endometrioid  85.7% 63.7 – 97.0 18/21  90.0% 55.5 – 99.8 9/10 
Clear Cell  78.6% 49.2 – 95.3 11/14  80.0% 28.4 – 99.5 4/5 
Mucinous  50.0% 11.8 – 88.2 3/6  66.7% 9.4 – 99.2 2/3 
Borderline  0.0% 0.0 – 84.2 0/2  - - - 
Undifferentiated  100.0% 2.5 – 100.0 1/1  100.0% 2.5 – 100.0 1/1 
Transitional Cell  50.0% 1.3 – 98.7 1/2  100.0% 2.5 – 100.0 1/1 
Brenner  66.7% 9.4 – 99.2 2/3  100.0% 15.8 – 100.0 2/2 
Mixed Subtypes  - - -  60.0% 36.1 – 80.9 12/20 
‡ More than one subtype of epithelial ovarian cancer was reported for 20 individuals.  The column “Multiple” reports the classification 
for all reported tumors either as single subtypes or mixed subtypes.  The column “Single” reports the classification of tumors assigned 
only a single subtype.  The 20 mixed subtypes are grouped together and their pathologies are as follows: serous/endometrioid (7), 
serous/clear cell (4), serous/borderline (2), serous/mucinous (1), serous/endometrioid/clear cell (2), serous/endometrioid/clear 
cell/mucinous (1), clear cell/mucinous (1), clear cell/endometrioid (1), transitional cell/Brenner (1).  Abbreviations: SN, sensitivity; SP, 
specificity; n, number of samples classified correctly; N, total number of samples being classified; 95% CI, 95% two-sided exact binomial 
confidence interval. 
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Table 5. Classification of Other Gynecologic Cancers by the 8-Biomarker Profile 
 
Cancer  Classified as Ovarian Cancer 95% CI n/N 
Cervical  100.0% 19.8 – 100.0 2/2 
Endometrial/uterine  53.8% 26.1 – 79.6 7/13 
Fallopian  80.0% 29.9 – 98.9 4/5 
Peritoneal  81.8% 47.8 – 96.8 9/11 
Extra-ovarian  100.0% 5.5 – 100.0 1/1 
Ovarian germ cell  100.0% 5.5 – 100.0 1/1 
Ovarian stromal cell  100.0% 5.5 – 100.0 1/1 
Ovarian transitional cell  100.0% 5.5 – 100.0 1/1 
Ovarian borderline (Low Malignant Potential)  54.8% 38.8 – 69.8 23/42 
Ovarian malignant mixed Mullerian tumor  85.7% 42.0 – 99.2 6/7 
Mixed Cancers  100.0% 46.3 – 100.0 5/5 
Abbreviations: n, number of samples classified as ovarian cancer; N, number of samples assayed; 95% CI, 95% two-sided exact binomial 
confidence interval.   
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